

Efficacy of Extended Letemovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

NCT06812598

Status	RECRUITING
Phase	Not Applicable
Sponsor	The First Affiliated Hospital of Soochow University
Enrollment	330 participants

Key Eligibility Criteria

Inclusion (8)

- The patients have decided to undergo an initial allogeneic hematopoietic stem cell transplantation (allo-HSCT).
 - The patients are ≥18 years old.
 - The patients are CMV seropositive prior to transplantation.
 - The patients have at least one high-risk factor for CMV reactivation, including:
 - (1) Haploidentical transplantation, HLA-mismatched transplantation, or unrelated donor transplantation.
- ... and 3 more (see full listing online)

Exclusion (13)

- Patients who have previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
 - Patients with evidence of CMV viremia at any time prior to enrollment.
 - Patients with a history of CMV end-organ disease within 6 months prior to enrollment.
 - Patients with suspected or known allergy to letemovir or any active or inactive components of similar drugs.
 - Patients with severe hepatic impairment (defined as Child-Pugh Class C).
- ... and 8 more (see full listing online)

Locations (1 total)

Hematology Department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China